Empower Cells, Change Lives

TACTIC-2 marks first in-human use of TAC-T cell therapy Phase 1/2 clinical trial will evaluate TAC01-HER2, Triumvira’s lead candidate, in patients with HER2-overexpressing solid tumors First patient dosed at MD Anderson Cancer Center in Houston, Texas AUSTIN, Texas...

AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa...

BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched. To come up with this list, BioSpace looked at companies that recently launched over the past few years with Series A...